

Manuscript Number: FOODCHEM-D-15-03601R1

Title: Hydroxytyrosol targets extracellular matrix remodeling by endothelial cells and inhibits both ex vivo and in vivo angiogenesis

Article Type: Research Article (max 7,500 words)

Keywords: angiogenesis; aortic ring assay; BAEC; CAM assay; hydroxytyrosol; MMP; TIMP; uPA

Corresponding Author: Dr. Miguel Angel Medina,

Corresponding Author's Institution: University of Málaga

First Author: Javier A García-Vilas

Order of Authors: Javier A García-Vilas; Ana R Quesada; Miguel Ángel Medina

Abstract: The health benefits of olive oil are attributed to their bioactive compounds, such as hydroxytyrosol. Previously, we demonstrated that hydroxytyrosol inhibits angiogenesis in vitro. The present study aimed to: i) get further insight into the effects of hydroxytyrosol on extracellular matrix remodeling; and ii) test whether hydroxytyrosol is able to inhibit angiogenesis ex vivo and in vivo. Hydroxytyrosol induced a shift toward inhibition of proteolysis in endothelial cells, with decreased expression of extracellular matrix remodeling-enzyme coding genes and increased levels of some of their inhibitors. Furthermore, this work demonstrated that hydroxytyrosol, at concentrations within the range of its content in virgin olive oil that can be absorbed from moderate and sustained virgin olive oil consumption, is a strong inhibitor of angiogenesis ex vivo and in vivo. These results suggest the need for translational studies to evaluate the potential use of hydroxytyrosol for angio-prevention and angiogenesis inhibition in clinical setting.

1 **Hydroxytyrosol targets extracellular matrix remodeling by endothelial cells and inhibits**
2 **both *ex vivo* and *in vivo* angiogenesis**

3 Javier A. García-Vilas^{a,b}, Ana R. Quesada^{a,b} and Miguel Ángel Medina^{a,b} *

4 ^aUniversidad de Málaga, Andalucía Tech, Departamento de Biología Molecular y Bioquímica,
5 Facultad de Ciencias, and IBIMA (Biomedical Research Institute of Málaga)

6 ^bCIBER de Enfermedades Raras (CIBERER), E-29071 Málaga, Spain

7
8
9 ***Corresponding author:** Dr. Miguel Ángel Medina, Departamento de Biología Molecular y
10 Bioquímica, Facultad de Ciencias, Universidad de Málaga, E-29071, Málaga. Phone: +34-
11 952137132. Fax. +34-952131674. E-Mail: medina@uma.es

12
13
14 **Running title:** Antiangiogenic hydroxytyrosol
15
16

17 **Abstract**

18 The health benefits of olive oil are attributed to their bioactive compounds, such as
19 hydroxytyrosol. Previously, we demonstrated that hydroxytyrosol inhibits angiogenesis *in vitro*.
20 The present study aimed to: i) get further insight into the effects of hydroxytyrosol on
21 extracellular matrix remodeling; and ii) test whether hydroxytyrosol is able to inhibit
22 angiogenesis *ex vivo* and *in vivo*. Hydroxytyrosol induced a shift toward inhibition of
23 proteolysis in endothelial cells, with decreased expression of extracellular matrix remodeling-
24 enzyme coding genes and increased levels of some of their inhibitors. Furthermore, this work
25 demonstrated that hydroxytyrosol, at concentrations within the range of its content in virgin
26 olive oil that can be absorbed from moderate and sustained virgin olive oil consumption, is a
27 strong inhibitor of angiogenesis *ex vivo* and *in vivo*. These results suggest the need for
28 translational studies to evaluate the potential use of hydroxytyrosol for angio-prevention and
29 angiogenesis inhibition in clinical setting.

30

31

32 **Keywords:** angiogenesis; aortic ring assay; bovine aorta endothelial cells (BAEC);
33 chorioallantoic membrane (CAM) assay; hydroxytyrosol; matrix metalloproteinase (MMP);
34 tissue inhibitor of metalloproteinase (TIMP); urokinase-type plasminogen activator (uPA)

35

36 1. Introduction

37 The phenolic compounds in extra virgin olive oil are bioactive compounds with well-
38 documented beneficial effects (Fortes, García-Vilas, Quesada & Medina, 2012; Owen et al.,
39 2000) these compounds are not essential in the sense that nutrients are. In fact, the European
40 Union has authorized a health claim for polyphenols, based on consumption of olive oil
41 polyphenols, for the protection of blood lipids from oxidative stress ("Commission Regulation
42 (EU) 432/2012 of 16 May 2012 establishing a list of permitted health claims made on foods,
43 other than those referring to the reduction of disease risk and to children's development and
44 health. O.J. 2012, L136/1," 2012). Hydroxytyrosol or 3,4-dihydroxyphenyl ethanol is claimed
45 to be the most important health-related phenolic compound of virgin olive oil (Lopez de Las
46 Hazas, Rubio, Kotronoulas, de la Torre, Sola & Motilva, 2015). Along with its cardioprotective
47 effects (Mnafgui et al., 2015; Samuel, Thirunavukkarasu, Penumathsa, Paul & Maulik, 2008),
48 beneficial effects of hydroxytyrosol for human health include its antifungal (Zoric et al., 2013),
49 antidiabetic (Tutino, Orlando, Russo & Notarnicola, 2015; Zheng, et al., 2015), neuroprotective
50 (De La Cruz, et al., 2015; Gallardo, Madrona, Palma-Valdes, Espartero & Santiago, 2015), anti-
51 inflammatory (Fuccelli, Fabiani, Sepporta & Rosignoli, 2015; Persia, Mariani, Fogal & Penissi,
52 2014; Silva et al., 2015) and antitumoral (Granados-Principal et al., 2014; Sirianni et al., 2010;
53 Sun, Luo, & Liu, 2014; Zhao et al., 2014) activities. In 2012, our group added the first
54 description of hydroxytyrosol as an anti-angiogenic compound able to inhibit several key steps
55 in the angiogenic process. In fact, we demonstrated that hydroxytyrosol (but not tyrosol)
56 induced endothelial cell apoptosis and changes in cell cycle distribution as well as inhibiting
57 endothelial cell proliferation, migration and differentiation into "capillary-like" tubes (Fortes et
58 al., 2012). Furthermore, that work also identified matrix metalloproteinase 2 (MMP-2) as one of
59 the molecular targets of the anti-angiogenic action caused by hydroxytyrosol. Since the
60 publication of that article, additional data have been published regarding the roles of
61 hydroxytyrosol as an anti-angiogenic compound. Several molecular targets have been identified
62 contributing to the anti-angiogenic effects of hydroxytyrosol, including inhibition of MMP-9,

63 cyclooxygenase 2 and vascular endothelial growth factor receptor-2 (VEGFR-2)
64 phosphorylation (Lamy, Ouanouki, Beliveau & Desrosiers, 2014; Scoditti et al., 2012; Scoditti
65 et al., 2014). Furthermore, hydroxytyrosol has been recently shown to have protective effects
66 against rheumatoid arthritis, an angiogenesis-dependent disease (Silva et al., 2015).

67 The identification of MMPs as molecular targets for hydroxytyrosol suggests that this
68 compound can alter extracellular matrix remodeling (Fortes, García-Vilas, Quesada & Medina,
69 2012; Scoditti et al., 2014), a key step in the angiogenic process. Therefore, the first aim of the
70 present work was to study the effects of hydroxytyrosol on key extracellular matrix remodeling
71 enzymes expressed in endothelial cells. On the other hand, in spite of the recent efforts to get
72 deep insights on the anti-angiogenic potential of hydroxytyrosol there is still no data available
73 demonstrating its potential inhibitory effects in *ex vivo* or *in vivo* models of angiogenesis. The
74 second aim of this work was to test the anti-angiogenic potential of hydroxytyrosol in the *ex*
75 *vivo* aortic ring and the *in vivo* CAM angiogenesis models.

76

77 **2. Materials and methods**

78 *2.1. Chemicals*

79 Supplements and other chemicals not listed in this section were obtained from Sigma
80 Chemicals Co. (St. Louis MO, USA). Cell culture media, penicillin, streptomycin and
81 amphotericin were purchased from Biowhittaker (Walkersville, MD, USA). Fetal bovine serum
82 (FBS) and human serum (HS) were products of Harlan-Seralb (Belton, United Kingdom).
83 Plastics for cell culture were supplied by NUNC (Rockilde, Denmark) and VWR (West Chester,
84 Pennsylvania, USA). Hydroxytyrosol was supplied by Extrasynthèse (Lyon, France).

85

86 *2.2. Cell culture*

87 Most of the procedures described in Materials and methods have been previously used by
88 our research group for other studies (see, for instance [Garcia-Vilas et al. 2013, Martínez-Poveda](#)

89 [et al. 2013](#)). Bovine aorta endothelial cells (BAEC) were isolated from bovine aortic arches, as
90 previously described (Gospodarowicz & Moran, 1975), and maintained in Dulbecco's modified
91 Eagle's medium (DMEM) containing glucose (1 g/L), glutamine (2 mM), penicillin (50
92 IU/mL), streptomycin (50 mg/L), amphotericin (1.25 mg/L), 10% fetal bovine serum.

93

94 *2.3. RNA isolation and purification and cDNA synthesis*

95 Cells at 80% of confluence in 6-well plates were treated with or without 1mM of
96 hydroxytyrosol for 24 h. After incubation, cells were harvested and washed (PBS). Total RNA
97 was isolated with the GeneElute Mammalian Total RNA Miniprep Kit (Sigma-Aldrich)
98 according to the purchaser's instructions.

99 cDNA synthesis was carried out with the iScript cDNA synthesis kit (BioRad).

100

101 *2.4. qPCR*

102 For quantitative RT-PCR (qPCR), total RNA isolation and complementary DNA synthesis
103 were performed as described above and PCR reactions were done using KAPA SYBR Fast
104 Master Mix (2x) Universal (KAPA Biosystems) in an Eco Real-Time PCR System. qPCR was
105 performed in triplicate for each sample in keeping with the manufacturer's instructions. All
106 qPCR data were normalized to GAPDH expression (Martínez-Poveda et al. 2013). Primers,
107 amplicon size, and qPCR conditions for each gene are shown in Table 1.

108

109 *2.5. Animals and ethical statement*

110 All experimental procedures with animals were conducted in accordance with the Spanish
111 Legislation (Real Decreto 53/2013, BOE, 34/-11421, 2013) in compliance with the European
112 Community Directive 2010/63/EU regulating the use and care of laboratory animals. The

113 protocols were approved by the Ethics Committee for Animal Experiments of the University of
114 Málaga.

115

116 2.6. *Ex vivo rat aortic ring assay*

117 Thoracic aortas were removed from 12 week old rats and immediately transferred to a
118 culture dish containing DMEM. The perioaortic fibroadipodise tissue was carefully removed
119 with fine microdissecting forceps and iridectomy scissors paying special attention not to
120 damage the aortic wall. Afterwards, 1-mm aortic rings were sectioned and embedded in a rat tail
121 interstitial collagen gel (1.5 mg/mL) prepared by mixing 7.5 volumes of 2 mg/mL collagen, 1
122 volume of 10x HBBS, 1.5 volumes of 186 mM NaHCO₃ and 0.1 volumes of 1 M NaOH to
123 adjust the pH to 7.4. Collagen gels containing the aortic rings were polymerized in cylindrical
124 agarose wells and kept in triplicate at 37°C in 60 mm diameter Petri dishes (bacteriological
125 polysterene, Falcon, Becton Dickinson, Lincoln Park, New Jersey). Each Petri dish contained 6
126 mL of MCDB131 medium supplemented with 1% L-glutamine, 25 mM NaHCO₃, 100 U/mL
127 penicillin, 100 µg/mL streptomycin, in presence of hydroxytyrosol or etanol (vehicle). Cultures
128 were kept at 37°C, 5% CO₂ in a humidified environment, and photographs were taken after 6, 9
129 and 14 days. The antiangiogenic response was quantified by microvessel counting according to
130 published criteria (Nicosia & Ottinetti, 1990).

131

132 2.7. *In vivo chorioallantoic membrane (CAM) assay*

133 Fertilized chick eggs were incubated horizontally at 38°C in a humidified incubator,
134 windowed by day 3 of incubation and processed by day 8. The indicated amount of
135 hydroxytyrosol was added to a 1% solution of methylcellulose in water, and 10 µL drops of this
136 solution were allowed to dry on a Teflon-coated surface in a laminar flow hood. Then, the
137 methylcellulose disks were implanted on the CAMs, and the eggs were sealed with adhesive
138 tape and returned to the incubator for 48 h (Garcia-Vilas et al. 2013). Negative controls were

139 always made with ethanol (vehicle) mixed with methylcellulose. After the reincubation, CAMs
140 were examined under a stereomicroscope. The assay was scored as positive when two
141 independent observers reported a significant reduction of vessels in the treated area.

142

143 *2.8. Statistical analysis*

144 For all of the assays, at least three independent experiments were carried out. Results are
145 expressed as means \pm SD. Statistical significance was determined by using Student's paired
146 simple test. Values of $p < 0.05$ were considered to be significant.

147

148 **3. Results**

149

150 *3.1. Hydroxytyrosol induces changes in the expression levels of genes involved in ECM* 151 *remodeling in endothelial cells*

152 To fulfil the first goal of our work, we analyzed by qPCR the effects of 1 mM
153 hydroxytyrosol treatment of BAEC for 24 h on the expression levels of messenger
154 corresponding to a number of genes involved in ECM remodeling. The primers, annealing
155 temperature and amplicon sizes are summarized in Table 1. Table 2 summarizes the qPCR
156 quantitative data for the 9 tested potential targets. Both MMP-1 and MMP-2 mRNA expression
157 levels were drastically diminished by hydroxytyrosol, whereas three out of four tissue inhibitors
158 of metalloproteinases (namely, TIMP-1, -2 and -4) mRNA expression levels were increased
159 several fold. On the other hand, the mRNA levels for urokinase-type plasminogen activator
160 (uPA), another ECM remodeling enzyme, were also drastically diminished upon hydroxytyrosol
161 treatment, whereas the levels of the messenger for its specific receptor (uPAR) increased more
162 than 20-fold. Finally, we could not detect any signal for plasminogen activator inhibitor 1 (PAI-
163 1) mRNA.

164

165 3.2. *Hydroxytyrosol has a very potent inhibitory effect on the ex vivo rat aortic ring*
166 *angiogenesis assay*

167 The second goal of this work was to test the anti-angiogenic potential of hydroxytyrosol in
168 the *ex vivo* aortic ring and the *in vivo* CAM angiogenesis models. Figure 1 clearly shows that
169 hydroxytyrosol was able to induce very strong inhibitory effects in the *ex vivo* aortic ring assay,
170 even at concentrations much lower than those used previously by us to show its *in vitro* anti-
171 angiogenic effects (Fortes, García-Vilas, Quesada & Medina, 2012). At 0.25 mM
172 hydroxytyrosol the inhibition of microvessel outgrowth from the aortic rings was complete after
173 6, 9 and 14 days of incubation. At 0.125 mM hydroxytyrosol we observed outgrowing of
174 proliferative endothelial cells from the aortic ring but these cells were not forming microvessel
175 tubes. Furthermore, there were partial inhibitory effects for 62.5 µM hydroxytyrosol.

176

177 3.3. *Hydroxytyrosol inhibits in vivo angiogenesis*

178 Figure 2 shows that in untreated, control CAMs, blood vessels form a spatially-oriented and
179 dense network of vascular structures with progressively smaller diameters as they branch.
180 Hydroxytyrosol-treated CAMs showed inhibited angiogenesis, as revealed by an inhibition of
181 new vessel formation within the area covered by the methylcellulose discs, a centrifugal growth
182 of peripheral vessels, avoiding the treated area, and an overall decrease in vascular density.
183 Table 3 summarizes the results obtained with the CAM assay. Positive, inhibitory effects were
184 observed in 90% of eggs treated with 800 nmol of hydroxytyrosol. The inhibition was still
185 observed in more than half of the CAMs treated with 400 nmol of hydroxytyrosol. For
186 treatments with 200 and 100 nmol of hydroxytyrosol, 42% and 13% of the eggs scored positive.
187 No inhibitory effect was observed in eggs treated with 50 nmol of hydroxytyrosol.

188

189 **4. Discussion**

190 As mentioned in the Introduction, a number of very different biological effects have been
191 shown for hydroxytyrosol, underscoring its preventive and pharmacological potential. Our
192 group demonstrated for the first time that hydroxytyrosol also behaves as an anti-angiogenic
193 compound *in vitro* (Fortes, García-Vilas, Quesada & Medina, 2012). One of the molecular
194 targets for this effect of hydroxytyrosol was the extracellular remodeling enzyme MMP-2, which
195 plays a key role in the basal membrane destruction needed for the migration and invasion of
196 proliferative endothelial cells during the angiogenic process (Stetler-Stevenson, 1999). This
197 result was consistent with the description by another independent research group of the
198 suppression of MMP-9 expression by hydroxytyrosol in both human endothelial cells (Scoditti,
199 et al., 2012) and activated human monocytes (Scoditti, et al., 2014). Our qPCR results (Table 2)
200 indicate that, indeed, hydroxytyrosol seems to have a global stimulating effect on ECM
201 remodeling by both decreasing the expression levels of genes coding for extracellular matrix
202 remodeling enzymes (MMP-1, MMP-2, uPA) and increasing the levels of some of their
203 inhibitors (TIMP-1, -2, and -4).

204 A particularly important molecular target of hydroxytyrosol is VEGFR-2, since it plays a key
205 role as a master regulator of the pro-angiogenic phenotype. In fact, it has been shown that
206 hydroxytyrosol is a very potent inhibitor of the specific autophosphorylation sites (Tyr951,
207 Tyr1059, Tyr1175, and Tyr1214) of VEGFR-2, thus inhibiting angiogenesis (Lamy, Ouanouki,
208 Beliveau, & Desrosiers, 2014). These and other molecular data strongly suggested that
209 hydroxytyrosol might have protective effects on angiogenesis-dependent diseases. This seems
210 to be the case for age-related macular degeneration and rheumatoid arthritis (Granner, Maloney,
211 Anteck, Correa & Burnier, 2013; Silva et al., 2015). Nonetheless, there is still need additional
212 pre-clinical data showing modulatory effects of hydroxytyrosol beyond the *in vitro* situation to
213 boost the interest to test the hydroxytyrosol potential for its clinical use. In this context, both *ex*
214 *vivo* and *in vivo* assays seem required and useful. To our knowledge, the only available study
215 showing an additional and indirect evidence of the anti-angiogenic effect of hydroxytyrosol *in*
216 *vivo* was the article showing that hydroxytyrosol suppresses the growth of human hepatocellular

217 carcinoma through the inactivation of both AKT and NF- κ B pathways (Zhao et al., 2014). In
218 that article, figure 5C shows a histogram with the quantification of microvessel density in
219 orthotopic hepatocellular carcinoma tumors stained for the microvessel marker CD31. In the
220 present work, we have used two very popular pre-clinical angiogenesis assays, namely,
221 the *ex vivo* aortic ring assay and the *in vivo* CAM assay. The *ex vivo* aortic ring assay
222 allows for the analysis of cell proliferation, migration, tubule-like formation, microvessel
223 branching and perivascular recruitment and remodeling (Baker et al., 2012). The CAM assay is
224 the most frequently used *in vivo* assay of angiogenesis (Ribatti, 2008). The results obtained to
225 fulfil the second aim of the present work have contributed to provide clear and remarkable
226 evidence that, indeed, the anti-angiogenic effects of hydroxytyrosol observed previously *in vitro*
227 are strongly confirmed by both *ex vivo* and *in vivo* angiogenesis assays carried out in the present
228 work (Figures 1 and 2, and Table 3).

229 Interestingly, the effects described in the present work were obtained with hydroxytyrosol
230 doses within the range described previously as absorbed from a sustained and moderate dose of
231 virgin olive oil, similar to that corresponding to its daily intake in a typical Mediterranean diet
232 (Miró-Casas et al., 2003).

233 The results presented in this work can be considered a step further toward translational
234 studies to be carried out in the near future regarding the potential use of hydroxytyrosol in
235 angioprevention and for the pharmacological inhibition of angiogenesis.

236

237 **Conflict of interest**

238 The authors declare that they have no financial or other conflict of interest.

239

240 **Acknowledgements**

241 This work was supported by grants BIO2014-56092-R (MINECO and FEDER) and P12-
242 CTS-1507 (Andalusian Government and FEDER). The “CIBER de Enfermedades Raras” is an

243 initiative from the ISCIII (Spain). The funders had no role in the study design, data collection
244 and analysis, decision to publish or preparation of the manuscript.
245

246 **References**

- 247 Baker, M., Robinson, S. D., Lechertier, T., Barber, P. R., Tavora, B., D'Amico, G.,
248 Jones, D. T., Vojnovic, B., & Hodivala-Dilke, K. (2012). Use of the mouse
249 aortic ring assay to study angiogenesis. *Nature Protocols*, 7(1), 89-104.
- 250 Commission Regulation (EU) 432/2012 of 16 May 2012 establishing a list of permitted
251 health claims made on foods, other than those referring to the reduction of
252 disease risk and to children's development and health. O.J. 2012, L136/1.
253 (2012).
- 254 De La Cruz, J. P., Ruiz-Moreno, M. I., Guerrero, A., Reyes, J. J., Benitez-Guerrero, A.,
255 Espartero, J. L., & Gonzalez-Correa, J. A. (2015). Differences in the
256 Neuroprotective Effect of Orally Administered Virgin Olive Oil (*Olea*
257 *europaea*) Polyphenols Tyrosol and Hydroxytyrosol in Rats. *Journal of*
258 *Agricultural and Food Chemistry*, 63(25), 5957-5963.
- 259 Fortes, C., García-Vilas, J. A., Quesada, A. R., & Medina, M. A. (2012). Evaluation of
260 the anti-angiogenic potential of hydroxytyrosol and tyrosol, two bio-active
261 phenolic compounds of extra virgin olive oil, in endothelial cell cultures. *Food*
262 *Chemistry*, 134, 134-140.
- 263 Fuccelli, R., Fabiani, R., Sepporta, M. V., & Rosignoli, P. (2015). The hydroxytyrosol-
264 dependent increase of TNF-alpha in LPS-activated human monocytes is
265 mediated by PGE2 and adenylate cyclase activation. *Toxicology In Vitro*, 29(5),
266 933-937.
- 267 Gallardo, E., Madrona, A., Palma-Valdes, R., Espartero, J. L., & Santiago, M. (2015).
268 Effect of intracerebral hydroxytyrosol and its nitroderivatives on striatal
269 dopamine metabolism: A study by in vivo microdialysis. *Life Sciences*, 134, 30-
270 35.
- 271 García-Vilas, J.A., Quesada, A.R., & Medina, M.A. (2013) 4-Methylumbelliferone
272 inhibits angiogenesis in vitro and in vivo. *Journal of Agricultural and Food*
273 *Chemistry*, 61, 4063-4071.
- 274 Gospodarowicz, D., & Moran, J. S. (1975). Mitogenic effect of fibroblast growth factor
275 on early passage cultures of human and murine fibroblasts. *The Journal of Cell*
276 *Biology*, 66(2), 451-457.
- 277 Granados-Principal, S., El-Azem, N., Pamplona, R., Ramirez-Tortosa, C., Pulido-
278 Moran, M., Vera-Ramirez, L., Quiles, J. L., Sanchez-Rovira, P., Naudi, A.,
279 Portero-Otin, M., Perez-Lopez, P., & Ramirez-Tortosa, M. (2014).
280 Hydroxytyrosol ameliorates oxidative stress and mitochondrial dysfunction in
281 doxorubicin-induced cardiotoxicity in rats with breast cancer. *Biochemical*
282 *Pharmacology*, 90(1), 25-33.
- 283 Granner, T., Maloney, S., Anteck, E., Correa, J. A., & Burnier, M. N., Jr. (2013). 3,4
284 dihydroxyphenyl ethanol reduces secretion of angiogenin in human retinal
285 pigment epithelial cells. *British Journal of Ophthalmology*, 97(3), 371-374.
- 286 Lamy, S., Ouanouki, A., Beliveau, R., & Desrosiers, R. R. (2014). Olive oil compounds
287 inhibit vascular endothelial growth factor receptor-2 phosphorylation.
288 *Experimental Cell Research*, 322(1), 89-98.
- 289 Lopez de Las Hazas, M. C., Rubio, L., Kotronoulas, A., de la Torre, R., Sola, R., &
290 Motilva, M. J. (2015). Dose effect on the uptake and accumulation of
291 hydroxytyrosol and its metabolites in target tissues in rats. *Molecular Nutrition*
292 *& Food Research*, 59(7), 1395-1399.
- 293 Martínez-Poveda, B., García-Vilas, J.A., Cárdenas, C., Melgarejo, E., Quesada, A.R., &
294 Medina, M.A. (2013). The brominated compound aerophysinin-1 inhibits

- 295 proliferation and the expression of key pro-inflammatory molecules in human
296 endothelial and monocyte cells. *Plos One*, 8(1), e55203.
- 297 Miró-Casas, E., Covas, M.I., Fitó, M., Farré-Albadalejo, M., Marrugat, J., & De la
298 Torre, R. (2003). Tyrosol and hydroxytyrosol are absorbed from moderate and
299 sustained doses of virgin olive oil in humans. *European Journal of Clinical
300 Nutrition*, 57, 186-190.
- 301 Mnafigui, K., Hajji, R., Derbali, F., Khlif, I., Kraiem, F., Ellefi, H., Elfeki, A., Allouche,
302 N., & Gharsallah, N. (2015). Protective Effect of Hydroxytyrosol Against
303 Cardiac Remodeling After Isoproterenol-Induced Myocardial Infarction in Rat.
304 *Cardiovascular Toxicology*.
- 305 Nicosia, R. F., & Ottinetti, A. (1990). Growth of microvessels in serum-free matrix
306 culture of rat aorta. A quantitative assay of angiogenesis *in vitro*. *Laboratory
307 Investigation*, 63(1), 115-122.
- 308 Owen, R. W., Giacosa, A., Hull, W. E., Haubner, R., Wurtele, G., Spiegelhalder, B., &
309 Bartsch, H. (2000). Olive-oil consumption and health: the possible role of
310 antioxidants. *The Lancet Oncology*, 1, 107-112.
- 311 Persia, F. A., Mariani, M. L., Fogal, T. H., & Penissi, A. B. (2014). Hydroxytyrosol and
312 oleuropein of olive oil inhibit mast cell degranulation induced by immune and
313 non-immune pathways. *Phytomedicine*, 21(11), 1400-1405.
- 314 Ribatti, D. (2008). Chick embryo chorioallantoic membrane as a useful tool to study
315 angiogenesis. *International Review of Cell Molecular Biology*, 270, 181-224.
- 316 Samuel, S. M., Thirunavukkarasu, M., Penumathsa, S. V., Paul, D., & Maulik, N.
317 (2008). Akt/FOXO3a/SIRT1-mediated cardioprotection by n-tyrosol against
318 ischemic stress in rat in vivo model of myocardial infarction: switching gears
319 toward survival and longevity. *The Journal of Agricultural and Food Chemistry*,
320 56(20), 9692-9698.
- 321 Scoditti, E., Calabriso, N., Massaro, M., Pellegrino, M., Storelli, C., Martines, G., De
322 Caterina, R., & Carluccio, M. A. (2012). Mediterranean diet polyphenols reduce
323 inflammatory angiogenesis through MMP-9 and COX-2 inhibition in human
324 vascular endothelial cells: a potentially protective mechanism in atherosclerotic
325 vascular disease and cancer. *Archives of Biochemical Biophysics*, 527(2), 81-89.
- 326 Scoditti, E., Nestola, A., Massaro, M., Calabriso, N., Storelli, C., De Caterina, R., &
327 Carluccio, M. A. (2014). Hydroxytyrosol suppresses MMP-9 and COX-2
328 activity and expression in activated human monocytes via PKCalpha and
329 PKCbeta1 inhibition. *Atherosclerosis*, 232(1), 17-24.
- 330 Silva, S., Sepodes, B., Rocha, J., Direito, R., Fernandes, A., Brites, D., Freitas, M.,
331 Fernandes, E., Bronze, M. R., & Figueira, M. E. (2015). Protective effects of
332 hydroxytyrosol-supplemented refined olive oil in animal models of acute
333 inflammation and rheumatoid arthritis. *The Journal of Nutritional Biochemistry*,
334 26(4), 360-368.
- 335 Sirianni, R., Chimento, A., De Luca, A., Casaburi, I., Rizza, P., Onofrio, A., Iacopetta,
336 D., Puoci, F., Ando, S., Maggiolini, M., & Pezzi, V. (2010). Oleuropein and
337 hydroxytyrosol inhibit MCF-7 breast cancer cell proliferation interfering with
338 ERK1/2 activation. *Molecular Nutrition & Food Research*, 54(6), 833-840.
- 339 Stetler-Stevenson, W. G. (1999). Matrix metalloproteinases in angiogenesis: a moving
340 target for therapeutic intervention. *The Journal of Clinical Investigation*, 103(9),
341 1237-1241.
- 342 Sun, L., Luo, C., & Liu, J. (2014). Hydroxytyrosol induces apoptosis in human colon
343 cancer cells through ROS generation. *Food & Function*, 5(8), 1909-1914.

- 344 Tutino, V., Orlando, A., Russo, F., & Notarnicola, M. (2015). Hydroxytyrosol Inhibits
345 Cannabinoid CB1 Receptor Gene Expression in 3T3-L1 Preadipocyte Cell Line.
346 *The Journal of Cellular Physiology*.
- 347 Zhao, B., Ma, Y., Xu, Z., Wang, J., Wang, F., Wang, D., Pan, S., Wu, Y., Pan, H., Xu,
348 D., Liu, L., & Jiang, H. (2014). Hydroxytyrosol, a natural molecule from olive
349 oil, suppresses the growth of human hepatocellular carcinoma cells via
350 inactivating AKT and nuclear factor-kappa B pathways. *Cancer Letters*, 347(1),
351 79-87.
- 352 Zheng, A., Li, H., Xu, J., Cao, K., Li, H., Pu, W., Yang, Z., Peng, Y., Long, J., Liu, J.,
353 & Feng, Z. (2015). Hydroxytyrosol improves mitochondrial function and
354 reduces oxidative stress in the brain of db/db mice: role of AMP-activated
355 protein kinase activation. *British Journal of Nutrition*, 113(11), 1667-1676.
- 356 Zoric, N., Horvat, I., Kopjar, N., Vucemilovic, A., Kremer, D., Tomic, S., & Kosalec, I.
357 (2013). Hydroxytyrosol expresses antifungal activity *in vitro*. *Current Drug*
358 *Targets*, 14(9), 992-998.
359
- 360

361 **Table 1.** Primers used for qPCR with indication of their respective annealing temperatures
 362 and amplicon sizes.
 363

Gene	Primers	Annealing temperature (°C)	Amplicon size (bp)
MMP-1	Forward: gacttagtccagaatacctg Reverse: caaagaattcctgcatttgc	60	121
MMP-2	Forward: gacatacatctttgctggagac Reverse: acgctcttcagacttgggtct	60	200
TIMP-1	Forward: gggacaccagaagtcaacca Reverse: ggcttggaaacctttatacatc	63	81
TIMP-2	Forward: aagcggtcagtgagaaggaa Reverse: ttcaggccctttgaacatc	65	112
TIMP-3	Forward: gcagcggaccacaacagcta Reverse: ccggatcacgatgtcggagt	68	150
TIMP-4	Forward: agggagagcctgaatcatca Reverse: gactgcatagcaagtgtg	65	68
uPA	Forward: cgccacacactgcttcag Reverse: ccccttgcgtgttggagtt	60	310
uPAR	Forward: gcccaatcctggagcttga Reverse: tcccttgcagctgtaacact	60	63
PAI-1	Forward: gcacaacccccacaggaaca Reverse: gtcccgatgaaggcgtcttt	65	81

364 **Table 2.** Relative expression values of mRNAs for some extracellular matrix remodelling
 365 enzymes and their inhibitors in BAEC treated with hydroxytyrosol.

	MMP-1	MMP-2	TIMP-1	TIMP-2	TIMP-3	TIMP-4	uPA	uPAR	PAI-1
BAEC	16.9 ± 0.5	0.28 ± 0.2	3857.3 ± 537.1	418.0 ± 123.9	14.76 ± 1.47	377.6 ± 209.6	20.95 ± 12.1	2195.8 ± 433.0	-

366 qPCR was carried out as described in Materials and Methods. All qPCR data were
 367 normalized with GAPDH expression levels. Data are given as means ± S.D. and they are
 368 percentages of expression taking the corresponding expression values in control, untreated cells
 369 as 100%.

370

371

372

373 **Table 3.** Inhibition of *in vivo* angiogenesis by hydroxytyrosol (HT) as determined by the
374 CAM assay.

HT (nmol/CAM)	Positive/Total	Inhibition (%)
0	0/8	0
50	0/6	0
100	1/8	13
200	5/12	42
400	5/8	63
600	5/7	71
800	9/10	90

375

376

377 **Figure legends**

378

379 **Fig. 1.** Hydroxytyrosol inhibits microvessel outgrowth in the *ex vivo* rat aortic ring assay.

380 (A) Representative samples of the aortic ring without or with treatment. (B) Quantification of
381 the area occupied by new microvessels in controls, controls treated with VEGF and rings treated
382 with 31.2 μ M or 62.5 μ M hydroxytyrosol and VEGF. The results are the mean \pm SD of three
383 different assays.

384

385 **Fig. 2.** Hydroxytyrosol inhibits angiogenesis *in vivo* in the CAM assay. Arrows point rebound
386 of vessels outward from the treated area. Asterisks indicate disrupted vessels.

387

388

389


390

391

392

Figure 1

[Click here to download high resolution image](#)



B)





Figure 2
[Click here to download high resolution image](#)

Control



HT (800 nmol)

